Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Killer Immunoglobulin-like Receptor 2DL2 (KIR2DL2)
- Target
- KIR2DL2
- Molecular classification
- Receptor, Type I transmembrane glycoprotein, Immunoglobulin-like receptor
01
Overview
Killer immunoglobulin-like receptor 2DL2 (KIR2DL2) is an inhibitory receptor expressed on NK cells and some T cells. It recognizes group C1 HLA-C allotypes (e.g., HLA-Cw1, Cw3, Cw7, Cw8), and upon binding, delivers an inhibitory signal to prevent NK cell activation. KIR2DL2 plays a role in maintaining self-tolerance and its engagement can impair CAR-T cell effector function. It is encoded by the KIR2DL2 gene, which exhibits high polymorphism.
- Other names
- Natural killer-associated transcript 6p58 natural killer cell receptor clone CL-43MHC class I NK cell receptorCD158 antigen-like family member B1
02
Mechanism of action
Inhibits NK cell activation upon binding to HLA-C1 ligands via ITIM signaling.
03
Biological functions
Immune responseRegulation of NK cell activityInhibitory signalingSelf-tolerance
04
Disease associations
InfectionCancerAutoimmunity
05
Safety considerations
Potential for inhibiting CAR-T cell activityPolymorphism and variability in KIR repertoire
Beyond the preview
Go deeper on Killer Immunoglobulin-like Receptor 2DL2 (KIR2DL2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Killer Immunoglobulin-like Receptor 2DL2 (KIR2DL2).